Topic: Abbvie

Investigative reporter Sharyl Attkisson released a report detailing the financial interests behind the transgender advocacy movement, identifying pharmaceutical companies as primary funders. The report highlights that Gilead Sciences, a major producer of HIV medications, and AbbVie, the manufacturer of the puberty-suppressing drug Lupron, are top donors to trans organizations. Critics argue this creates a "Transgender Leviathan" where medical profits drive social policy and pediatric healthcare decisions.

Major food corporations like Nestle and Abbott are developing "companion products" specifically for consumers taking GLP-1 weight loss medications. These products, such as protein shakes and fiber blends, aim to address side effects like muscle mass loss and "Ozempic ass." Startups are also entering the market with prebiotic supplements marketed as "nature's Ozempic" to mimic the drug's effects through natural means.

Pharmaceutical giant AbbVie donated $100 million to the Ronald McDonald House, citing benefits from recent corporate tax cuts. While critics feared tax reform would cap individual charitable deductions and hurt non-profits, large corporations appear to be increasing their contributions. This suggests that major philanthropic efforts are being sustained by corporate windfalls rather than small individual donors.